At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This arrangement, ...

Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...

A lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors who purchased shares of Regeneron ...

Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

(NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: ...

TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230, citing increased competition and lower revenue estimates for EYLEA®, a key product. The firm pointed to ...

Regeneron Pharmaceuticals has built its success on a foundation of innovative drug development, with key products including Eylea for eye diseases and Dupixent for various inflammatory conditions.

which could compete with Regeneron Pharmaceuticals’ Eylea. The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025. If approved ...

Regeneron Pharmaceuticals (NASDAQ:REGN), a leading biotechnology company with a market capitalization of $77 billion, finds itself at a critical juncture as it navigates challenges to its flagship ...